A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
5
5
2020
medline:
12
6
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
There is a need for easily accessible tuberculosis unit cost data, as well as an understanding of the variability of methods used and reporting standards of that data. The aim of this systematic review was to descriptively review papers reporting tuberculosis unit costs from a healthcare provider perspective looking at methodological variation; to assess quality using a study quality rating system and machine learning to investigate the indicators of reporting quality; and to identify the data gaps to inform standardised tuberculosis unit cost collection and consistent principles for reporting going forward. We searched grey and published literature in five sources and eight databases, respectively, using search terms linked to cost, tuberculosis and tuberculosis health services including tuberculosis treatment and prevention. For inclusion, the papers needed to contain empirical unit cost estimates for tuberculosis interventions from low- and middle-income countries, with reference years between 1990 and 2018. A total of 21,691 papers were found and screened in a phased manner. Data were extracted from the eligible papers into a detailed Microsoft Excel tool, extensively cleaned and analysed with R software (R Project, Vienna, Austria) using the user interface of RStudio. A study quality rating was applied to the reviewed papers based on the inclusion or omission of a selection of variables and their relative importance. Following this, machine learning using a recursive partitioning method was utilised to construct a classification tree to assess the reporting quality. This systematic review included 103 provider perspective papers with 627 unit costs (costs not presented here) for tuberculosis interventions among a total of 140 variables. The interventions covered were active, passive and intensified case finding; tuberculosis treatment; above-service costs; and tuberculosis prevention. Passive case finding is the detection of tuberculosis cases where individuals self-identify at health facilities; active case finding is detection of cases of those not in health facilities, such as through outreach; and intensified case finding is detection of cases in high-risk populations. There was heterogeneity in some of the reported methods used such cost allocation, amortisation and the use of top-down, bottom-up or mixed approaches to the costing. Uncertainty checking through sensitivity analysis was only reported on by half of the papers (54%), while purposive and convenience sampling was reported by 72% of papers. Machine learning indicated that reporting on 'Intervention' (in particular), 'Urbanicity' and 'Site Sampling', were the most likely indicators of quality of reporting. The largest data gap identified was for tuberculosis vaccination cost data, the Bacillus Calmette-Guérin (BCG) vaccine in particular. There is a gap in available unit costs for 12 of 30 high tuberculosis burden countries, as well as for the interventions of above-service costs, tuberculosis prevention, and active and intensified case finding. Variability in the methods and reporting used makes comparison difficult and makes it hard for decision makers to know which unit costs they can trust. The study quality rating system used in this review as well as the classification tree enable focus on specific reporting aspects that should improve variability and increase confidence in unit costs. Researchers should endeavour to be explicit and transparent in how they cost interventions following the principles as laid out in the Global Health Cost Consortium's Reference Case for Estimating the Costs of Global Health Services and Interventions, which in turn will lead to repeatability, comparability and enhanced learning from others.
Sections du résumé
BACKGROUND
There is a need for easily accessible tuberculosis unit cost data, as well as an understanding of the variability of methods used and reporting standards of that data.
OBJECTIVE
The aim of this systematic review was to descriptively review papers reporting tuberculosis unit costs from a healthcare provider perspective looking at methodological variation; to assess quality using a study quality rating system and machine learning to investigate the indicators of reporting quality; and to identify the data gaps to inform standardised tuberculosis unit cost collection and consistent principles for reporting going forward.
METHODS
We searched grey and published literature in five sources and eight databases, respectively, using search terms linked to cost, tuberculosis and tuberculosis health services including tuberculosis treatment and prevention. For inclusion, the papers needed to contain empirical unit cost estimates for tuberculosis interventions from low- and middle-income countries, with reference years between 1990 and 2018. A total of 21,691 papers were found and screened in a phased manner. Data were extracted from the eligible papers into a detailed Microsoft Excel tool, extensively cleaned and analysed with R software (R Project, Vienna, Austria) using the user interface of RStudio. A study quality rating was applied to the reviewed papers based on the inclusion or omission of a selection of variables and their relative importance. Following this, machine learning using a recursive partitioning method was utilised to construct a classification tree to assess the reporting quality.
RESULTS
This systematic review included 103 provider perspective papers with 627 unit costs (costs not presented here) for tuberculosis interventions among a total of 140 variables. The interventions covered were active, passive and intensified case finding; tuberculosis treatment; above-service costs; and tuberculosis prevention. Passive case finding is the detection of tuberculosis cases where individuals self-identify at health facilities; active case finding is detection of cases of those not in health facilities, such as through outreach; and intensified case finding is detection of cases in high-risk populations. There was heterogeneity in some of the reported methods used such cost allocation, amortisation and the use of top-down, bottom-up or mixed approaches to the costing. Uncertainty checking through sensitivity analysis was only reported on by half of the papers (54%), while purposive and convenience sampling was reported by 72% of papers. Machine learning indicated that reporting on 'Intervention' (in particular), 'Urbanicity' and 'Site Sampling', were the most likely indicators of quality of reporting. The largest data gap identified was for tuberculosis vaccination cost data, the Bacillus Calmette-Guérin (BCG) vaccine in particular. There is a gap in available unit costs for 12 of 30 high tuberculosis burden countries, as well as for the interventions of above-service costs, tuberculosis prevention, and active and intensified case finding.
CONCLUSION
Variability in the methods and reporting used makes comparison difficult and makes it hard for decision makers to know which unit costs they can trust. The study quality rating system used in this review as well as the classification tree enable focus on specific reporting aspects that should improve variability and increase confidence in unit costs. Researchers should endeavour to be explicit and transparent in how they cost interventions following the principles as laid out in the Global Health Cost Consortium's Reference Case for Estimating the Costs of Global Health Services and Interventions, which in turn will lead to repeatability, comparability and enhanced learning from others.
Identifiants
pubmed: 32363543
doi: 10.1007/s40273-020-00910-w
pii: 10.1007/s40273-020-00910-w
pmc: PMC7437656
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Pagination
819-837Subventions
Organisme : Bill & Melinda Gates Foundation
ID : OPP1109722
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
S Afr Med J. 1997 Apr;87(4):451-5
pubmed: 9254789
Am J Trop Med Hyg. 2010 Jun;82(6):1131-9
pubmed: 20519613
Int J Tuberc Lung Dis. 2013 Oct;17(10):1336-40
pubmed: 24025387
Int J Tuberc Lung Dis. 2002 May;6(5):396-405
pubmed: 12019915
Int J Tuberc Lung Dis. 2014 May;18(5):541-6
pubmed: 24903790
Trop Med Int Health. 2016 Feb;21(2):176-82
pubmed: 26610176
Cost Eff Resour Alloc. 2008 Oct 24;6:20
pubmed: 18947436
Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S80-5
pubmed: 12971658
PLoS One. 2015 Feb 06;10(2):e0117009
pubmed: 25658592
Pharm World Sci. 2008 Jun;30(3):281-6
pubmed: 18204974
Int J Tuberc Lung Dis. 2005 Aug;9(8):877-83
pubmed: 16104634
Lancet. 2002 Jun 8;359(9322):1980-9
pubmed: 12076553
Bull World Health Organ. 2006 Jul;84(7):528-36
pubmed: 16878226
Int J Tuberc Lung Dis. 2000 Mar;4(3):246-51
pubmed: 10751071
PLoS One. 2008;3(12):e4057
pubmed: 19129940
Int J Tuberc Lung Dis. 2000 Mar;4(3):240-5
pubmed: 10751070
Scand J Public Health. 2006;34(1):83-91
pubmed: 16449048
Medicina (Kaunas). 2013;49(7):335-40
pubmed: 24375246
Lancet. 1991 Nov 23;338(8778):1305-8
pubmed: 1682693
Thorax. 2013 Mar;68(3):247-55
pubmed: 22717944
Pan Afr Med J. 2014 Aug 05;18:277
pubmed: 25489371
Cad Saude Publica. 2011 May;27(5):944-52
pubmed: 21655845
Bull World Health Organ. 2006 Jun;84(6):437-45
pubmed: 16799727
Am J Respir Crit Care Med. 2011 Apr 15;183(8):1103-11
pubmed: 21148723
PLoS One. 2010 Feb 17;5(2):e9158
pubmed: 20174642
Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S14-20
pubmed: 12971650
PLoS One. 2013;8(1):e54587
pubmed: 23349933
Cost Eff Resour Alloc. 2005 Jul 14;3:6
pubmed: 16018806
Trans R Soc Trop Med Hyg. 2014 Jul;108(7):402-7
pubmed: 24864048
Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S72-9
pubmed: 12971657
Trop Med Int Health. 2009 Jul;14(7):748-53
pubmed: 19392738
Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S29-37
pubmed: 12971652
Int J Tuberc Lung Dis. 2013 Mar;17(3):368-72
pubmed: 23407225
J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):576-84
pubmed: 26167618
Int J Technol Assess Health Care. 2003 Spring;19(2):407-20
pubmed: 12862197
J Clin Epidemiol. 1993 Jul;46(7):631-6
pubmed: 8326348
PLoS One. 2012;7(8):e43307
pubmed: 22905254
Southeast Asian J Trop Med Public Health. 1992 Jun;23(2):195-9
pubmed: 1439970
S Afr Med J. 1998 Mar;88(3 Suppl):380-3
pubmed: 9608310
AIDS. 1995 Mar;9(3):267-73
pubmed: 7755915
Int J Tuberc Lung Dis. 2014 Aug;18(8):939-45
pubmed: 25199008
BMC Infect Dis. 2005 Dec 12;5:111
pubmed: 16343340
Clin Infect Dis. 2008 Aug 15;47(4):487-95
pubmed: 18636955
BMC Public Health. 2006 Aug 15;6:209
pubmed: 16911786
Afr J AIDS Res. 2019 Dec;18(4):263-276
pubmed: 31779571
PLoS Med. 2012;9(11):e1001348
pubmed: 23209384
Health Policy Plan. 2002 Jun;17(2):178-86
pubmed: 12000778
BMC Public Health. 2012 Jun 21;12:469
pubmed: 22720878
Int J Tuberc Lung Dis. 2014 Dec;18(12):1443-8
pubmed: 25517809
Eur Respir J. 2011 Dec;38(6):1393-7
pubmed: 21659413
Bull World Health Organ. 2015 Nov 1;93(11):775-84
pubmed: 26549905
BMC Public Health. 2007 May 18;7:84
pubmed: 17511864
Int J Tuberc Lung Dis. 2013 Aug;17(8):1056-64
pubmed: 23827030
PLoS Med. 2006 Sep;3(9):e352
pubmed: 16968123
Health Policy Plan. 2006 Sep;21(5):353-64
pubmed: 16940301
Health Policy. 2006 Feb;75(3):272-9
pubmed: 16325960
Int J Tuberc Lung Dis. 2007 Jul;11(7):747-54
pubmed: 17609049
PLoS One. 2016 May 12;11(5):e0155101
pubmed: 27171380
Am J Trop Med Hyg. 2014 May;90(5):866-872
pubmed: 24615134
Health Econ. 2016 Feb;25 Suppl 1:53-66
pubmed: 26763594
Cost Eff Resour Alloc. 2006 Jun 06;4:11
pubmed: 16756653
Int J Tuberc Lung Dis. 1998 Mar;2(3):235-41
pubmed: 9526197
Springerplus. 2012 Oct 24;1:40
pubmed: 23961366
Health Policy Plan. 2009 Jan;24(1):55-62
pubmed: 19056804
Probl Tuberk. 1998;(3):9-13
pubmed: 9691679
Int J Tuberc Lung Dis. 2010 Aug;14(8):1024-31
pubmed: 20626948
East Mediterr Health J. 2012 Apr;18(4):393-8
pubmed: 22768704
Int J Tuberc Lung Dis. 2016 Sep;20(9):1212-8
pubmed: 27510248
Int J Tuberc Lung Dis. 2009 Jun;13(6):705-12
pubmed: 19460245
Trop Med Int Health. 2003 Mar;8(3):242-50
pubmed: 12631315
PLoS Med. 2012;9(8):e1001281
pubmed: 22879816
Int J Tuberc Lung Dis. 2015 Feb;19(2):172-8
pubmed: 25574915
PLoS One. 2012;7(5):e36966
pubmed: 22693561
Lancet Glob Health. 2017 Jul;5(7):e710-e719
pubmed: 28619229
Trop Med Int Health. 2006 Sep;11(9):1466-74
pubmed: 16930269
Trans R Soc Trop Med Hyg. 2015 Dec;109(12):783-92
pubmed: 26626341
J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):e84-93
pubmed: 26258564
Bull World Health Organ. 2002;80(6):445-50
pubmed: 12132000
Health Econ. 2016 Feb;25 Suppl 1:95-115
pubmed: 26786617
Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S56-62
pubmed: 12971655
PLoS One. 2013;8(2):e57527
pubmed: 23469014
J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):83-90
pubmed: 26049281
PLoS One. 2013 Apr 04;8(4):e59546
pubmed: 23593145
Southeast Asian J Trop Med Public Health. 2002 Jun;33(2):321-30
pubmed: 12236432
BMC Health Serv Res. 2016 Jan 22;16:27
pubmed: 26800677
BMJ. 1997 Nov 29;315(7120):1407-11
pubmed: 9418087
Open Forum Infect Dis. 2015 Jan 08;2(1):ofu121
pubmed: 25884008
Trop Med Int Health. 2015 Oct;20(10):1337-45
pubmed: 25975868
Soc Sci Med. 1997 Jun;44(12):1805-16
pubmed: 9194242
Rev Saude Publica. 2005 Feb;39(1):122-8
pubmed: 15654469
Pharmacoeconomics. 2015 Sep;33(9):939-55
pubmed: 25939501
Cost Eff Resour Alloc. 2008 Jan 23;6:2
pubmed: 18215255
BMC Public Health. 2010 Mar 30;10:173
pubmed: 20353567
Int J Tuberc Lung Dis. 2002 Dec;6(12):1083-90
pubmed: 12546116
BMC Health Serv Res. 2014 Aug 19;14:353
pubmed: 25138659
Int J Tuberc Lung Dis. 2015 Sep;19(9):1078-83, i-iii
pubmed: 26260829
Trop Med Int Health. 2010 Mar;15(3):277-86
pubmed: 20070633
Trop Med Int Health. 2013 Jan;18(1):109-16
pubmed: 23170876
PLoS One. 2013 Jul 23;8(7):e69267
pubmed: 23935970
Public Health Action. 2012 Sep 21;2(3):61-5
pubmed: 26392953
Trop Med Int Health. 2012 Sep;17(9):1142-51
pubmed: 22686606
Soc Sci Med. 1995 May;40(9):1203-12
pubmed: 7610426
J Public Health Afr. 2011 Sep 05;2(2):e19
pubmed: 28299060
Lancet Respir Med. 2013 Aug;1(6):471-8
pubmed: 24429245
Health Policy. 2009 Dec;93(2-3):214-24
pubmed: 19729220
BMC Infect Dis. 2009 Aug 26;9:139
pubmed: 19709423